Skip to main content
. 2021 Jul 30;46(5):601–611. doi: 10.1007/s13318-021-00706-z
The occurrence of similar infections in patients with primary (PADs) and secondary (SADs) antibody deficiencies suggests there may be value to using diagnostic criteria for PADs to increase the safety of SADs.
Atacicept can be used as a retrospective example to demonstrate the potential of the mathematical modeling of early clinical data to increase drug safety by refining the inclusion criteria for patient selection.